ERNA Valuation

Ernexa Therapeutics Inc

Add to Watchlist

Advanced Chart

1.330

-0.05(-3.623%)1D

Overview
Forecast
Valuation
Earnings

ERNA Relative Valuation

ERNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ERNA is overvalued; if below, it's undervalued.

Historical Valuation

Ernexa Therapeutics Inc (ERNA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.42. The fair price of Ernexa Therapeutics Inc (ERNA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.33

Fair

-0.01

Trailing

Forward

0.00

EV/EBITDA

Ernexa Therapeutics Inc. (ERNA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.20

EV/EBIT

Ernexa Therapeutics Inc. (ERNA) has a current EV/EBIT of -0.20. The 5-year average EV/EBIT is -3.41. The thresholds are as follows: Strongly Undervalued below -14.93, Undervalued between -14.93 and -9.17, Fairly Valued between 2.35 and -9.17, Overvalued between 2.35 and 8.11, and Strongly Overvalued above 8.11. The current Forward EV/EBIT of -0.20 falls within the Historic Trend Line -Fairly Valued range.

0.00

Ernexa Therapeutics Inc. (ERNA) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-0.28

P/OCF

Ernexa Therapeutics Inc. (ERNA) has a current P/OCF of -0.28. The 5-year average P/OCF is -0.54. The thresholds are as follows: Strongly Undervalued below -2.93, Undervalued between -2.93 and -1.73, Fairly Valued between 0.66 and -1.73, Overvalued between 0.66 and 1.86, and Strongly Overvalued above 1.86. The current Forward P/OCF of -0.28 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Ernexa Therapeutics Inc. (ERNA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Ernexa Therapeutics Inc (ERNA) has a current Price-to-Book (P/B) ratio of 2.24. Compared to its 3-year average P/B ratio of 1.26 , the current P/B ratio is approximately 77.58% higher. Relative to its 5-year average P/B ratio of -6.18, the current P/B ratio is about -136.24% higher. Ernexa Therapeutics Inc (ERNA) has a Forward Free Cash Flow (FCF) yield of approximately -141.60%. Compared to its 3-year average FCF yield of -166.02%, the current FCF yield is approximately -14.71% lower. Relative to its 5-year average FCF yield of -119.24% , the current FCF yield is about 18.75% lower.

2.24

P/B

Median3y

1.26

Median5y

-6.18

-141.60

FCF Yield

Median3y

-166.02

Median5y

-119.24

Competitors Valuation Multiple

The average P/S ratio for ERNA's competitors is 0.57, providing a benchmark for relative valuation. Ernexa Therapeutics Inc Corp (ERNA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ERNA.O

Ernexa Therapeutics Inc

NovaBay Pharmaceuticals Inc

Bolt Biotherapeutics Inc

Kiora Pharmaceuticals Inc

Processa Pharmaceuticals Inc

Loss

9.52M

DWTX.O

Dogwood Therapeutics Inc

Loss

9.48M

Performance Decomposition

Market capitalization of ERNA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ERNA in the past 1 year is driven by Unknown.